ArticleAvicenna journal of phytomedicine
The neuroprotective effect of BSA-based nanocurcumin against 6-OHDA-induced cell death in SH-SY5Y cells.
Article in Avicenna journal of phytomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 16 citations in OpenAlex.
- A comparison between adjuvant and delivering functions of iron oxide and calcium phosphate nanoparticles, using a model protein againstClinical and experimental vaccine research · 2025Article
- Neuroprotective Effects of Curcumin in Neurodegenerative Diseases.Foods (Basel, Switzerland) · 2024Review
- Adverse Effects of Non-Metallic Nanoparticles in the Central Nervous System.Materials (Basel, Switzerland) · 2023Review
- Curcumin-Based Nanomedicines in the Treatment of Inflammatory and Immunomodulated Diseases: An Evidence-Based Comprehensive Review.Pharmaceutics · 2023Review
- Nanocurcumin and curcumin prevent N, N'-methylenebisacrylamide-induced liver damage and promotion of hepatic cancer cell growth.Scientific reports · 2022Article
- Article
- Curcumin-loaded nanoparticles: a novel therapeutic strategy in treatment of central nervous system disorders.International journal of nanomedicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveParkinson's disease (PD) is regarded as the second most common neurodegenerative disease affecting elderly population. There is a tendency toward finding natural cures to suppress the initiation and progression of this disease. Some epidemiological studies indicated lower incidence of PD in populations that consume curry. Curcumin, as the main ingredient of turmeric, has been supposed to have a protective role against PD progression. However, low bioavailability of curcumin is still a challenge in evaluation of the therapeutic potential of this substance. In this study, we aimed to produce a BSA-based nanocurcumin to assess its effect on 6-hydroxydopamine (6-OHDA)-induced death and Akt signaling disruption in SH-SY5Y cells. MATERIALS AND
methodsBSA-based nanocurcumin was produced using desolvation method. Human neuroblastoma cells were treated with OHDA with/without different doses of nanocurcumin and MTT test was used to assess their viability besides observing cells morphological changes. The protective doses of nanocurcumine were chosen according to MTT results and western blot studies were done to assess p-Akt/t-Akt ratio.
results6-OHDA exposure led to decreased cell viability, while nanocurcumin at doses of 400 and 500 nM prevented cell death. Moreover, this nanoformulation of curcumin restored p-Akt/t-Akt decrement induced by 6-OHDA. The protective effect of BSA-based nanocurcumin was estimated to be at least 4 time higher than that of natural curcumin according to the MTT results.
conclusionIt seems that BSA-based nanocurcumin can be regarded as a potent substitute for natural curcumin in protecting SH-SY5Y cell as a cellular model of PD.
Indexed as
Identifiers
30984574PMC6448549W2899433726What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.